CORT · Corcept Therapeutics Inc · Investor Relations

Sean Maduck to Retire; Justin Gunn Appointed President, Endocrinology REDWOOD CITY, Calif. --(BUSINESS WIRE)--Sep. 23, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic,

REDWOOD CITY, Calif. --(BUSINESS WIRE)--Sep. 18, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the

Revenue of $256.1 million, a 32 percent increase over the same period in 2025 Korlym ® and authorized generic product revenue of $208.6 million Lifyorli ™ product revenue of $47.6 million Increase in 2026 revenue guidance to $1.1 – $1.2 billion Net income of $43.0 million, compared to $35.1

REDWOOD CITY, Calif. --(BUSINESS WIRE)--Jul. 22, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2026. The company will also host a conference call that day at 5:00 p.m.

REDWOOD CITY, Calif. --(BUSINESS WIRE)--Jun. 17, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the

New data from CATALYST and MOMENTUM trials presented at American Diabetes Association’s (ADA) 86 th Scientific Sessions In the CATALYST trial, patients with hypercortisolism treated with Korlym exhibited clinically and statistically significant improvements in hemoglobin A1c (HbA1c) and clinically

REDWOOD CITY, Calif. --(BUSINESS WIRE)--May 29, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the

REDWOOD CITY, Calif. --(BUSINESS WIRE)--May 27, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the

87 percent reduction in risk of death compared to patients who received placebo (hazard ratio: 0.13, p-value: 0.0001) REDWOOD CITY, Calif. --(BUSINESS WIRE)--Apr. 30, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of

Revenue of $164.9 million, compared to $157.2 million in first quarter 2025 Increase in 2026 revenue guidance to $950 – $1,050 million Net loss of $31.8 million, compared to net income of $20.5 million in first quarter 2025 Cash and investments of $515.4 million at March 31, 2026 Lifyorli ™